Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya.
J Gastrointest Cancer. 2022 Dec;53(4):958-964. doi: 10.1007/s12029-021-00723-w. Epub 2021 Oct 3.
Mortality from pancreatic cancer has risen fast in the past two decades in East Africa, including Kenya. However, there was a paucity of conclusive data about the survival of pancreatic cancer patients in the study setting. Hence, this study aimed to assess the survival outcomes of pancreatic cancer patients at Kenyatta National Hospital.
A hospital-based retrospective cohort analysis was used to evaluate the survival outcomes among pancreatic cancer patients treated in the study setting from 1 January 2015 to 31 December 2019. A total of 64 eligible pancreatic cancer patients were included in the study. In the pre-designed data abstraction tool, the data were collected by reviewing the medical records of the patients. The data were analyzed using the Statistical Package for the Social Sciences version 22 software. The mean survival time was estimated using Kaplan-Meier survival analysis. Cox regression analysis was employed to estimate the predictors of mortality among pancreatic cancer patients.
The mean age of the study participants was 60.38 ± 12.61 years. Most of the patients had adenocarcinoma (96.9%) and were diagnosed at an advanced stage of the disease. The overall mean and median survival estimate for pancreatic cancer was 48.7 ± 9.7 and 39.0 ± 23.9 months, respectively. The present study showed that the overall survival rate of pancreatic cancer patients was 79.7%.
The mortality rate of pancreatic cancer in the present study was 20%. The overall mean survival estimate for pancreatic cancer was 48.7 ± 9.7 months, and the majority had disease progression in the last follow-up period.
在过去的二十年中，东非（包括肯尼亚）的胰腺癌死亡率迅速上升。然而，关于研究环境中胰腺癌患者的生存情况，缺乏确凿的数据。因此，本研究旨在评估肯尼亚国家医院胰腺癌患者的生存结果。
采用基于医院的回顾性队列分析，评估 2015 年 1 月 1 日至 2019 年 12 月 31 日期间在研究环境中接受治疗的胰腺癌患者的生存结果。共有 64 名符合条件的胰腺癌患者纳入本研究。在预先设计的数据提取工具中，通过查阅患者的病历收集数据。使用社会科学统计软件包第 22 版分析数据。使用 Kaplan-Meier 生存分析估计平均生存时间。采用 Cox 回归分析估计胰腺癌患者死亡的预测因素。
研究参与者的平均年龄为 60.38±12.61 岁。大多数患者患有腺癌（96.9%），且处于疾病晚期。胰腺癌的总体平均和中位生存估计值分别为 48.7±9.7 和 39.0±23.9 个月。本研究显示，胰腺癌患者的总体生存率为 79.7%。
本研究中胰腺癌的死亡率为 20%。胰腺癌的总体平均生存估计值为 48.7±9.7 个月，大多数患者在最后一次随访期间出现疾病进展。
